Patent · US Active

6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma

US9120811B2 · kind B2 · utility

25Cited by

19References

10Claims

0Family size

Assignee

GILEAD CONNECTICUT, INC. · US

Inventors

Scott A. Mitchell · East Haven, US
Kevin S. Currie · North Branford, US

Key dates

Filing date	May 9, 2014
Grant date	Sep 1, 2015
Priority date	—
Expiry date	May 9, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/91205
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are imidazopyrazine compounds, including 6-(1H-indazol-6-yl)-N-(4 -moirpholinophenyl)imidazo-[1,2-a]pyrazine-8-amine:and methods for using the imidazopyrazine compounds for treating diseases and disorders responsive to the inhibition of Syk activity, including leukemia and lymphoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.